AU682188B2 – Method to detect bone and other connective tissue disorders in humans and animals
– Google Patents
AU682188B2 – Method to detect bone and other connective tissue disorders in humans and animals
– Google Patents
Method to detect bone and other connective tissue disorders in humans and animals
Download PDF
Info
Publication number
AU682188B2
AU682188B2
AU68648/94A
AU6864894A
AU682188B2
AU 682188 B2
AU682188 B2
AU 682188B2
AU 68648/94 A
AU68648/94 A
AU 68648/94A
AU 6864894 A
AU6864894 A
AU 6864894A
AU 682188 B2
AU682188 B2
AU 682188B2
Authority
AU
Australia
Prior art keywords
free
pyd
dpd
crosslinks
bone
Prior art date
1989-12-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU68648/94A
Other versions
AU6864894A
(en
Inventor
S P Robins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rowett Research Institute
Original Assignee
Rowett Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1989-12-30
Filing date
1994-07-21
Publication date
1997-09-25
1994-07-21
Application filed by Rowett Research Institute
filed
Critical
Rowett Research Institute
1994-11-24
Publication of AU6864894A
publication
Critical
patent/AU6864894A/en
1997-09-25
Application granted
granted
Critical
1997-09-25
Publication of AU682188B2
publication
Critical
patent/AU682188B2/en
2010-12-28
Anticipated expiration
legal-status
Critical
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N2800/00—Detection or diagnosis of diseases
G01N2800/10—Musculoskeletal or connective tissue disorders
G01N2800/108—Osteoporosis
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S436/00—Chemistry: analytical and immunological testing
Y10S436/811—Test for named disease, body condition or organ function
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S436/00—Chemistry: analytical and immunological testing
Y10S436/811—Test for named disease, body condition or organ function
Y10S436/813—Cancer
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S436/00—Chemistry: analytical and immunological testing
Y10S436/815—Test for named compound or class of compounds
Abstract
The invention is directed to antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids. Methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy are also disclosed. Such methods comprise assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator.
Description
8~1~68~1181 11 1Y r II-r 1
AUSTRALIA
Patents Act 1990 THE ROWETT RESEARCH INSTITUTE
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT 0* off.
0:0.
000.0′, 5
S
Invention Title: Method to detect bone and other connective tissue disorders in humans and animals The following statement is a full description of this invention including the best method of performing it known to us:-
III
ICU-sl METHOD TO DETECT BONE AND OTHER CONNECTIVE TISSUE DISORDERS IN HUMANS AND ANIMALS Technical Field The invention relates to methods of diagnosis in medical and veterinary contexts. More specifically, it concerns methods to assess bone and other connective tissue metabolism by detecting free crosslinks formed by collagen degradation in biological fluids, such as urine.
.e Background Art The association of collagen as a major structural material in a multiplicity of tissues, including bone, cartilage, skin, tendons, dentine and various soft tissues is well known. It is also known 20 that the fiber structure of collagen is stabilized by crosslinking. The presence of the fluorescent pyridinium ring system as a non-reducible crosslink in collagen was reported by Fujimoto, et al., J Biochem (1978) 83:863-867. The Fujimoto paper reported isolation of a S 25 fluorescent peptide from pronase digestion of bovine Achilles tendon collagen. The isolated hydrolyzed pyridinoline (Pyd) was thought to contain three residues of hydroxylysine and it was recognized that, prior to hydrolysis, peptide fragments were attached to the pyridinoline moiety. Further work on characterization was conducted by Gunja-Smith, et al., Biochem J (1981) 197:759-762, using hydrolyzed urine, and advantage was taken of the presence of the pyridinoline in urine by Robins, Biochem J (1982) 207:617-620, who linked
I
-2pyridinoline obtained from hydrolyzed urine to a carrier to raise antibodies. The antibodies were then employed in an immunoassay to determine the concentration of pyridinoline in hydrolyzed urine. The procedure was stated by Robins as useful to provide an index of the degradation of certain forms of mature collagen by analysis of physiological fluids.
In all of the foregoing, hydrolyzates were employed to obtain total pyridinoline since much of the crosslink retained peptide extensions of the hydroxylysyl residues responsible for its formation. Thus, in order to obtain a homogenous preparation containing the pyridinium ring, a preliminary hydrolysis step was necessary.
By 1982, it was established that there were two pathways of crosslink formation depending on whether lysine or hydroxylysine residues were present in the telopeptides from which these crosslinks were derived (Robins, in «Collagen in Health and Disease» (1982) 20 Weiss, et al., eds., pages 160-178, Churchill Livingstone, Edinburgh). This was stated to result in a specificity of crosslinking whereby in soft tissues, such as skin, reducible aldimine linkages are formed from oxidized lysyl residues, whereas in cartilage and bone S 25 these bonds, initially formed from hydroxylysine aldehydes, undergo a spontaneous rearrangement to more stable 3xoimine crosslinks. These bonds undergo further reaction to form 3-hydroxy-pyridinium crosslinks. The stable crosslinking pyridinoline analog involving lysine rather than hydroxylysine in the helix portion was identified and quantified by Ogawa, et al., Biochem Biophys Res Commune (1982) 107:1251-1257; Eyre, et al., Anal Biochem (1984) 137:380-388, and designated deoxypyridinoline (Dpd). This material was then believed i I I -3to be restricted to bone collagen, although amounts vary between species.
Further work by Robins, Biochem J (1983) 215:167-173, provided evidence for the existence of glycosylated pyridinoline in bone. Robins proposed a structure which showed the derivation of the ring from three residues of hydroxylysine and also showed that alkali hydrolyzates of collagen provided an O-galactosyl derivative substituted at the sidechain hydroxy group.
As this material was extremely labile to mild acid treatment, this material would not have been present in .samples of hydrolyzed tissue or body fluid.
Fujimoto, et al., J Bicchem (1983) 94:1133-1136, chromatographed unhydrolyzed urine samples 15 and showed that the 3-hydroxypyridinium ring portion was present in substantial proportion as the «free» form, the three hydroxylysyl-derived residues which composed it did not contain further peptide extensions.
On amino acid analysis, whereas pyridinoline isolated 20 from an acid hydrolyzate of collagen gave an asymmetric peak, «free» urinary pyridinoline gave a symmetric peak.
The authors concluded this to be due to isomerization by epimerization of the hydroxylysine moiety of the pyridinoline system during hydrolysis. In addition, 25 relationship of levels of total pyridinoline (after hydrolysis) to age was determined by these workers as a ratio to creatinine levels. It was found that the ratio was high in the urine of children but decreased with age until growth ceases. It was further found that this ratio is relatively constant in adults, but increases slightly in old age. The authors speculate that this may correspond to the loss of bone mass observed in old age.
Attempts were also made to characterize the above-mentioned peptide extensions. Robins, et I II I Ir ~a -L C~ I I -4al., Biochem J (1983) 215:175-182, proposed that in cartilage-derived type II collagen, the pyridinoline links two C-terminal telopeptide chains with a single chain of the helical peptide. An additional pyridinoline crosslink, with the ring derivatized to other peptides, was thought to link two N-terminal non-helical peptides with a third chain in the helical portion of the molecule. The studies were conducted by isolating the fluorescent pyridinoline crosslinks from tissues by specific cleavage with CNBr, thus preserving peptide sequences as extensions of the hydroxylysyl residues forming the ring. The crosslink was localized in the .collagen fibers by determining the amino acid sequences of these extensions.
S* 15 In a paper similar in approach to that of Robins (supra), Wu, et al., Biochemistry (1984) 23:1850-1857, conducted CNBr cleavage of mature cartilage and determined the sequence of the peptide extension residues of the hydroxylysyl participants in the 20 pyridinium ring. Their conclusions were similar to those of Robins.
Robins, et al., Biochim Biophys Acta (1987) 914:233-239, used CNBr digestion of bone derived collagen to localize the crosslinks in the type I collagen structure. These authors concluded that the proportions of the crosslink derived from lysine and that derived from hydroxylysine were present in the same proportions in each of the isolated peptide forms. They also concluded that this showed that these two crosslink analogs occupy the same loci in the collagen fiber and that the form apparently derived from one lysyl participant appears to arise through incomplete hydroxylation of the appropriate lysine residues in the helix. Amino acid analysis indicated that the crosslinks I I LL
~II_
must be situated at two locations involving both the Nand C- terminal telopeptide regions.
Henkel, et al., Eur J Biochem (1987) 165:427-436, determined the amino acid sequences associated with the crosslinks in type I collagen isolated from aorta. These sequences are different from those obtained for type II collagen. Similar results were found by Eyre, et al., FEBS (1987) 2:337-341, who demonstrated that the crosslinks from type IX and type II collagens displayed distinctive peptides attached to the pyridinoline crosslinks.
PCT application W089/04491 to Washington Research Foundation proposes a urinary assay for measuring bone resorption by detection in urine of the specific crosslinks, characterized by their peptide extensions, associated with bone collagen. The assay relies on quantifying the concentration of peptides in a body fluid where the peptide fragments having a pyridinium crosslink are derived from bone collagen resorption. Two specific entities having peptide extensions presumed to be associated with bone collagen are described. These are obtained from the urine of patients suffering from Paget’s disease, a disease known to involve high rates of bone formation and destruction.
Macek, et al., Z Rheumatol (1987) :46:237-240, proposed an assay for osteoarthrosis which -ernds upon the peptides associated with the crosslinks from collagen breakdown. In this approach, the urine sample was size-separated for peptides of molecular weight greater than 10 kd, which peptides were then separated by HPLC using a fluorescence detector to determine those fractions containing the fluorescence due to the pyridinium ring. The spectra obtained from patients with osteoarthrosis were compared to those from I~ 1 i I C RBI~IIII I IP -6healthy patients, and it was easily demonstrable that the multitude of fluorescent peaks associated with the diseased condition was absent from the healthy counterpart. Furthermore, urine from the same diseased patient two weeks after total endoprosthesis of the diseased hip, thereby decreasing the products of osteoarthrosis, gave a spectrum of fluorescent peaks which more closely resembled that of normals.
Furthermore, the osteoarthrosis spectrum was readily distinguished from that obtained from patients with rheumatoid arthritis. The closer resemblance of the rheumatoid arthritis spectrum to that of the spectrum from normal controls was attributed by the authors to the higher activity of proteases in rheumatoid arthritis.
15 This was presumed to digest collagen structures into smaller fragments not detectable in their system.
Study of the elevated levels of total 3hydroxypyridinium ring crosslinks in hydrolyzed urine of patients with rheumatoid arthritis has also been suggested as a method to diagnose this disease by Black, et al., Annals of Rheumatic Diseases (1989) 48:641- 644. The levels of «hydrolyzed» crosslink for patients with rheumatoid arthritis (expressed as a ratio of this compound to creatinine) were elevated by a factor of 5 as 25 compared to controls. In this method, crosslinks derived from hydroxylysine were distinguishable from those derived from lysine; only the hydroxylysine-derived crosslinks were measurably increased. In a more extensive study using hydrolyzed urines, Seibel et al., J Rheumatol (1989 16:964-970, showed significant increases in the excretion of bone-specific crosslinks relative to controls in both rheumatoid and osteoarthritis, but the most marked increases for hydroxylysine-derived pyridinium were in patients with rheumatoid arthritis.
II I II PPBPI~YI~B~PI; -7- While measures related to the presence of collagen-derived crosslinks have been used as indices of the degradation of specific collagen types, including that of bone, conversely, efforts have been made to identify markers of bone formation. Delmas, et al., J Bone Mineral Res (1986) 1:333-337, used the level of GLA- protein in serum as a marker for bone formation in children; the same group, Brown, et al., used a similar assay to assess bone formation in post-menopausal osteoporosis (Lancet (19b4) 1091-1093.
There are many conditions in humans and animals which are characterized by a high level of bone resorption and by an abnormal balance between bone formation and bone resorption. Among the best known of 15 these are osteoporosis and Paget’s disease. However, abnormalities in bone metabolism occur in a variety of other conditions including the progress of benign and malignant tumors of the bone and metastatic cancers which have been transferred to bone cells from, for example, prostate or breast initial tumors. Other conditions include osteopetrosis, osteomalacial diseases, rickets, abnormal growth in children, renal osteodystrophy, and a drug-induced osteopenia. Irregularities in bone metabolism are also often side effects of thyroid treatments and thyroid conditions per se, such as primary hypothyroidism and thyrotoxicosis as well as Cushing’s disease. It would be useful to have a diagnostic which readily recognizes a subject’s condition as an irregularity in bone metabolism, even without defining the precise syndrome from among the possible choices, such as those listed here. Additional tests within the sphere of known bone diseases can be performed once it is established that this is the subset of problems from which diagnosis will emerge.
r~IIPI~PII~I~ l–pll -8- The invention provides just such a screening test, which is general for bone metabolism abnormalities.
Disclosure of the Invention The invention provides a straightforward, and noninvasive, if desired, test to identify subjects who have conditions which are characterized by abnormalities in the formation and resorption of bone and the balance between them. The test is based on the quantitation of tp) native free pyridinoline or deoxypyridinoline crossiinks derived from collagen degradation which are present in Sbiological fluids such as serum and urine. The test is specifically directed to either or both of the forms of crosslinks which occur in such fluids in forms 15 independent of additional amino acid sequence associated with the condensed lysyl or hydroxylysyl residues which constitute the collagen-derived crosslinks.
Accordingly, in one aspect, the invention is directed to a method to diagnose the presence of 20 disorders associated with bone metabolism abnormalities, which method comprises assessing the level of native free 9 crosslinks in a biological fluid of the subject. This level is then compared with the level of the native free crosslinks in normal subjects. Elevated levels of native 25 free crosslinks indicate the presence of such S» abnormalities.
This method can be fine-tuned by assessing the level of these degradation products in comparison with indicators of bone formation. Additional information as to the condition of the subject can be obtained if it is found that the difference between the level of bone resorption, as characterized by the presence of native free crosslinks in the biological fluid, and the level of bone formation, as characterized by the level of the 1–M CCBBRII~ I1ILo~arroaa~Rla~l~llrra~—— -9indicator, is the same or different from that of normal subjects. In general, those suffering from disorders which deplete the skeletal structure are characterized by larger differences between the resorption and formation rates, where resorption predominates.
Thus, a further aspect of the invention is directed to a method to diagnose the presence of the above-mentioned metabolism abnormalities which comprises comparing the levels of an indicator of bone formation in a biological fluid with the level of native free crosslinks in a biclogical fluid from the same individual and comparing the difference between these levels and the differences found for normal subjects. Elevated differences between bone resorption and bone formation 15 indicate problems in maintaining skeletal integrity.
It has been found by the inventor herein that antibodies which bind to hydrolyzed free crosslinks obtained from tissues or biological fluids by treatment with acids are not cross-reactive with native free S 20 crosslinks–either those which contain a lysyl sidechain or those with a hydroxylysyl sidechain. However, antibodies may be prepared which are specific for these free crosslinks. These antibodies may not be cross-reactive with the hydrolyzed forms; for purposes of assessing biological samples directly, this does not o matter, as the hydrolyzed forms are not present. These antibodies may be prepared, if desired, so as to distinguish between the lysyl and hydroxylysyl sidechaincontaining native free crosslink forms. Based on previous experience with polyclonal antibodies against hydrolyzed pyridinoline, the antibodies are likely to distinguish the free forms from the native peptidecontaining forms.
i I 4 Accordingly, another aspect of the invention is directed to antibodies specifically immunoreactive with the native free crosslinks or with either the lysyl or hydroxylysyl forms of native fee crosslinks, or with the glycosylated forms thereof.
Another aspect of the invention is a method to identify subsets of arthritic disease by determining the breakdown of other connective tissues, including cartilage, which method comprises determining the ratio of hydroxylysyl sidechain crosslinks to lysyl sidechain crosslinks (Pyd/Dpd) in a biological fluid of a subject and comparing said ratio to that in normal 10 controls, wherein an increase in said ratio in said subjects over normal controls indicates cartilage breakdown in said subject.
Another aspect is a method of determining the presence of an indicator of connective tissue formation which, in combination with free crosslink levels, provides an assessment of the subject’s metabolic state.
Still another aspect provides a kit for immunoassay determination of the amount or concentration of native free crosslinks in a biological fluid, said crosslinks A ing determinabl, as total free crosslinks or those selected .I from N-Pyd and N-Dpd. The kit includes a set of containers at least one of which contains an antibody or fragment thereof specifically immunoreactive 20 with native free total crosslinks or N-Pyd or N-Dpd and at least one of which contains an additional reagent for conduct of the immunoassay such as a label along with instructions for the conduct of the assay. Preferably, the biological fluid is a serum or urine. The free crosslinks may then be determined as total native free crosslinks. However, the free crosslinks can be determined individually as lysyl sidechain crosslinks (N-Dpd) or as hydroxylysyl sidechain crosslinks (N-Pyd), or as glycosylated Pyd, or any combination of these. The kit may further include a container an antibody of fragment thereof specifically immunoreactive with one or more bone formation indicators.
V I -11crosslinks can be determined individually as I sidechain crosslinks (Dpd) ur a xylysyl sidechain crosslinks (P s glycosylated Pyd, or any nation of these.
In still another aspect, the invention is directed to the use of the assay kits containing the antibodies of the invention or fragments thereof as specific reagents for the crosslinks to be detected.
Brief Description of the Drawings Figure 1 shows a chromatographic trace of pyridinoline obtained from an acid hydrolyzate superimposed on a trace of the pyridinoline obtained without hydrolysis from urine. The figure further compares the o 15 elution pattern as determined by fluorescence with the elution pattern as determined by reaction with antipyridinoline antibody prepared from hydrolyzate.
Modes of Carrying Out the Invention The invention provides an improvement over the presently available methods to diagnose bone disorders or other diseases characterized by abnormalities in collagen metabolism. The invention method utilizes variations in the levels of collagen-derived pyridinium crosslinks in 25 biological fluid as an index of these abnormalities.
*o Prior art methods have involved the hydrolysis of a sample, typically urine, to provide analyte in the form of hydrolyzed crosslinks, free of peptide sidechains, which can then be quantitated in an immunoassay using antibodies raised with respect to the hydrolyzed crosslinks. While this method provides useful information, the preliminary hydrolysis required prevents the assay from becoming a simple clinical assay run directly on an untreated biological sample.
I
~CLI_- -12- It has been found, by the inventors herein, that antibodies raised with respect to the hydrolyzed forms of the pyridinium crosslink do not cross-react either with the free crosslinks present in urine or other biological fluids, or with these crosslinks conjugated to peptides prior to hydrolysis. Thus, the antibodies presently available in the art cannot be used directly with an untreated biological sample.
The present invention overcomes this disadvantage by providing reagents which can be reacted directly with the biological sample to determine the crosslinks present in free form as the diastereomer present prior to hydrolysis. As shown in the examples below, direct measurement of these free and unhydrolyzed crosslinks provides data which are comparable to those obtainable only through the presently available, more complex assay.
Some background information as to the crosslink structures involved will be useful: Nature of the Crosslinks The abbreviations Dpd and Pyd will be used herein to denote the two known forms of the isolated crosslink itself. Pyd or pyridinoline refers to crosslinks formed *wherein the ring N is from the E amino group of an hydroxylsyl residue; Dpd or deoxypyridinoline refers to crosslinks formed wherein the ring N is from the e amino group of a lysyl residue. (Various methods of denoting these variations have been used; for example, HP has been used to designate the «hydroxylsyl» form, and LP has been used to refer to the «lysyl» form.) Specifically, Dpd is believed to represent compounds of the formula:
I
-13-
CHCH-NHCOOH
HOOCH
1
NCHCHCH
2 O 0H I
CH
2
CH,
CH,
CHNH
2
COOH
and Pyd is believed to describe compounds of the formula: 00 CHCHNL4H, COO H 15 OOCH,-NCHCH,CH~ OH
CHOH
CH,
It is seen that both forms of crossliniks are 25 1,4,5 trisubstituted 3-hydroxypyridinium residues. Pyd has zt free hydroxyl group on the sidechain which can be glycosylated, and it is known to be glycosylated in some tissues. The glycosylation is labile to acid, and also to base, but to a lesser degree. Pyd has been shown to occur as Gal-Pyd; the inventor herein has also demonstrated the presence of Glc.Gal-Pyd in urine (see PCT application WO 89/00715). These forms of free Pyd have the acetals
I
-14-
CHOH
HO O
OH
CHOH CHOH HO and OH0
O
OH OH OH HO OH conjugated to the sidechain hydroxyl, respectively.
It is seen that Dpd contains three chiral centers–those of the three a-amino positions in the sidechains. Pyd contains four such centers, as there is an additional chiral center at the sidechain hydroxyl position. Presumably, in the unhydrolyzed samples, whether derivatized further to peptides or not, the three a-amino groups are derived from the natively occurring 15 L-enantiomers, and the OH is in a configuration also determined by the biological system.
As set forth in the Background section above, a substantial proportion of the crosslinks present in urine (about 40% in adults) is in the form of «free» 26 crosslinks–i.e., there are no peptide chains conjugated to the Pyd, glycosylated Pyd, or Dpd structures shown above, even before hydrolysis of the sample is conducted.
Thus, by «free» crosslink is meant compounds of the formulas shown above.
25 It is noted that with respect to Pyd and Dpd, the chirality of the chiral centers is not specified.
Thus, «free,» refers to these crosslinks, whether or not they have been subjected to hydrolysis conditions. The present work demonstrates that these «free» crosslinks differ in chirality when obtained in their «native» form, as compared to their «hydrolyzed» form. As used herein, «native free» crosslinks refers to Dpd or Pyd or its glycosylated forms as they occur in free form in the biological sample; «hydrolyzed free» crosslinks refers to -11M I_ I_ these structures as they occur in hydrolysates. Of course, as the glycosidic bond is labile to the hydrolysis conditions, «hydrolyzed free» crosslinks will not contain sugars.
As the native free crosslinks are the product of the biological system, it is assumed that the biologically favored chirality occurs at all three or four chiral centers. Presumably the three chiral centers represented by the a-amino groups of the sidechains are in the L configuration, as in the naturally occurring amino acid, and the chirality of the carbon containing the sidechain hydroxyl in Pyd is also representative of a single configuration. This is confirmed by the results shown in Figure 1, in which the dotted line represents 15 the result of ion-exchange chromatography on sulfonated polystyrene beads (7 j) equilibrated with sodium citrate performed with the previously isolated Pyd in its native free form. As seen in Figure 1, the Pyd isolated directly from urine elutes at a single peak. This is consistent with the presence of only a single diastereomer.
After hydrolysis, however, the hydrolyzed free Pyd elutes as a mixture, shown by the solid line in Figure 1. This is consistent with racemization at the 25 chiral centers to obtain a mixture of diastereomers which no lcr.ger exhibit identical chromatographic behavior.
Similar results are obtained comparing native free Dpd with hydrolyzed free Dpd.
The «native free» crosslinks thus differ from hydrolyzed free forms of crosslinks. It appears that during conventional acid hydrolysis racemization occurs which changes the configuration of some of the molecules.
However, enhancement of the yield of total «native free» crosslinks in the biological sample could also be
I
I
-16obtained by proteolytic treatment of total native Dpd and Pyd to liberate the «native free» crosslink form. In addition, the crosslinks per se are identical across species, and other species besides human could be utilized to prepare native free crosslink standards for use in the assay system or for use as immunogens. In particular, porcine urine contains high amounts of native free crosslinks. Any source of the biologically important diastereomer could be used.
It has been shown by the inventor herein that the antibodies raised against the free Pyd which is generated as the result of hydrolysis–i.e., wherein the immunogen is obtained by treating the biological fluid or tissue in concentrated acid so as to destroy peptide 15 linkages and separating Pyd from Dpd–show little or no cross-reactivity with native free forms of either Dpd or Pyd. Furthermore, antibodies raised against the Pyd formed from the hydrolyzate cross-react only slightly with Dpd thus formed. Antibodies raised against Pyd from 20 an acid hydrolyzate of bone or cartilage do cross-react with the crosslink in urine after acid hydrolysis.
~A typical set of results is shown in Table 1.
Table 1 presents the results of an ELISA assay using antiserum obtained by immunization with the Pyd hydrolyzate isolated from bone. The ELISA uses this o* hydrolyzate as antigen, and the results are given in terms of the ability of the candidate crosslink to inhibit the binding of the hydrolyzate antigen to the antiserum. Using this criterion, antibodies which were obtained by immunization of rabbits against Pyd isolated from an acid hydrolyzate of cartilage or bone were only cross-reactive with Pyd in its native free form from urine (U-Pyd) although completely cross-reactive with Pyd after hydrolysis in acid of the purified native, free
~I~
-17crosslink isolated from urine. These antibodies, further, were 20% cross-reactive with Dpd isolated from the same bone hydrolyzate and were less than 1% cross-reactive with Dpd in its native free form from urine (U-Dpd); about 70% of the reactivity with these antibodies was recovered after acid hydrolysis of the native free form (Table 1).
Table 1 pmol required for 50% Cross inhibition reaction 15 Pyd from hydrolyzate 1.6 100 of bone Free Pyd from urine (U-Pyd) 29.6 U-Pyd from urine 1.5 107′ hydrolyzed in acid 2 Dpd from hydrolyzate 8.1 of bone Free Dpd from urine (U-Dpd) >260 <1 U-Dpd from urine 11.5 14 hydrolyzed in acid This is further shown in Figure 1, which, as stated above, presents the result of ion-exchange chromatography on sulfonated polystyrene beads (7 A) equilibrated with sodium citrate. The elution patterns for the free Pyd and the acid hydrolyzate of urine were determined by fluorescence. Antibodies raised against the acid hydrolyzate are shown to react significantly only with ii -18the hydrolyzate. The discrepancy in reactivity of the two major hydrolyzate peaks is attributable to the differing immunogenicity of these two fractions.
Preparation of Antibodies to Native Free Crosslinks Antibodies are prepared to the native free crosslink either as a total fraction or, preferably, to each component of this fraction. Gross separation of the pyridinium linkage in its "free" forms from the fragments containing protein can be achieved, for example, by the method of Fujimoto, J Biochem (1983) 94:1133-1136 (supra). In this preparation, a concentrate of urine is 9* applied to a Sephadex G-10 column and the total pyridinium-containing fractions eluted. The eluate is then applied to a column of phosphocellulose equilibrated with sodium citrate, and eluted with salt. This rather simple procedure results in the "free" crosslinks as a single peak. As the sample is not subjected to hydrolysis conditions this peak contains not only the Dpd :i 20 and Pyd forms, but also glycosylated Pyd including Gal-Pyd and Glc.Gal-Pyd as described above. Further separation of this native free crosslink fraction is then conveniently conducted by standard methods, for example using ion exchange on sulfonated polystyrene beads as described above, or using HPLC. Typical protocols for this separation are found, for example, in Black, et al., Anal Biochem (1988) 169:197-203; Seibel, et al., J Rheumatol.(1989) 16:964-970.
Antibody preparation is by conventional techniques including injection of the mixture or the individual components conjugated to carrier into suitable mammalian subjects such as rabbits or mice according to immunological protocols generally known in the art. The materials are conjugated to carriers such as BSA or I I e 'Ic~c- -19tetanus toxoid using standard conjugation methods to enhance immunogenicity. Sera are titrated to determine antibody formation with respect to the immunogen. If desired, spleen cell or peripheral blood lymphocytes may be harvested and immortalized to produce cultures of cells capable of continuous production of monoclonal antibodies immunoreactive with the desired component.
These preparations have enhanced specificity with respect to the individual components.
Thus, polyclonal antisera can be obtained which are specifically immunoreactive with the native free form of the crosslinks occurring in biological fluids, in particular in urine. By "specifically immunoreactive" is meant that the serum is capable of forming complexes with the native free crosslink forms in the biological fluid with sufficiently greater affinity in comparison to other materials in the fluid to permit determination of the native free forms in an immunoassay. Some portion of the polyclonal antiserum prepared either with respect to the mixture of native free forms or with respect to the individual components may crossreact with the native forms having peptide chains attached; assays can be standardized either by preparation of monoclonal antibodies which do not thus crossreact, or by standardizing to account for this crossreactivity.
The availability of routine techniques to obtain :monoclonal antibody preparations permits reproducible reproduction of antibodies of the desired specificity.
Thus, by utilizing a screening procedure which utilizes as a criterion the ability of the immortalized cell supernatant to immunoreact with, for example, native free Pyd, but to fail to react either with native free Dpd or forms of the crosslinks which are further conjugated to peptides, a reliable source of antibodies which react only with native free Pyd can be obtained. Conversely, it may be advantageous to use, in assessment of biological samples, cocktails of antibodies with these unique specificities so that all native free forms are determined.
Immortalized cell lines which secrete antibodies of the desired specificity can be cultured in vitro for the production of practical quantities of the desired monoclonals using mammalian cell techniques known in the art. Such culture techniques are now available on a commercial scale. In addition, the immortalized cell lines may be injected into mice and a somewhat cruder preparation of the monoclonals isolated as the ascites *fluid. The antibody preparation may also be affinity purified if desired using the immunogen as an affinity ligand.
It should be noted that while it is clear that antibodies prepared with respect to the hydrolyzed free forms of the collagen-derived crosslinks failed to react 20 with the native free forms, it is not of importance whether the converse is true, since hydrolyzed forms are not present in unhydrolyzed biological samples. Thus, screening procedures to assure the absence of this crossreactivity are unnecessary.
Conduzt of Immunoassays I Accordingly, by utilization of an immunoassay with the antibodies prepared as above it is possible to assay a biological fluid sample without prior fractionation or hydrolysis. The specificity for the desired form of native free Pyd or Dpd or both is supplied by the antibody preparation.
The immunoassays themselves are conducted using the variety of standard assay protocols generally known in
-II~
-21the art. As is generally understood, the assay is constructed so as to rely on the interaction between the specific antibody and the desired analyte for specificity and to utilize some means to detect the complex formed by the analyte and the antibody. The complex formation may be between the antibody itself or an immunologically reactive fragment thereof such as an Fab, Fab', or F(ab') 2 fragments. The antibody or immunologically reactive fragment thereof may be complexed to solid support and used as a capture antibody for the analyte.
This protocol may be run in a direct form, wherein the formation of analyte/antibody complex is detected by a fluorescent, radioactive or enzymatic label, or may be o:.e run in a competitive format wherein a labeled standard 15 competes with analyte for the antibody. The format may "also be constructed as an agglutination assay or the complex may be precipitated by addition of a suitable precipitant to the reaction mixture. The specific design of the immunoassay protocol is open to a wide variety of choice, and the number of clinical assay devices and protocols available in the art is multitudinous.
The antibodies and reagents for the conduct of an immunoassay using standard detection protocols--i.e., for example radioisotope labeling, fluorescent labeling or 25 ELISA, either in a direct or competitive format can eo eI conveniently be supplied as kits which include the .e necessary components and instructions for the assay.
Since antibodies can be raised specifically to the forms of the native free crosslinks which comprise the various forms thereof, the ratios of these components can be determined as well as their individual levels and their total.
Thus, the assay can be designed to include antibodies or immunologically reactive fragments thereof rl I Illsll~l-~ -22which will result in.determination of total native free crosslinks, or determination of native free Pyd, Dpd, Gal-Pyd, or Glc.Gal-Pyd, or any desired combination thereof. Since the levels of the Pyd and Dpd crosslinks in various tissues can be determined, alteration in their relative amounts can be used as an index for degradation of the particular tissue in question. For example, for most normal adults, the ratio of Pyd/Dpd stays constant throughout adulthood. As bone has a Pyd/Dpd ratio of 4/1 and appears to be the major source of liberated Dpd, an elevation in the ratio of Dpd/Pyd may be indicative of bone degradation. (Although aorta also contains Dpd, its turnover rate is low.) Assessment of the level of Dpd in biological fluids also yields a result which is 15 relatively bone-specific. However, it appears that in many instances where a bone disorder is suspected, the total free crosslink level (Dpd Pyd) can also be used as a measure when additional information is present..
When the symptoms do not suggest a disease of cartilage 20 such as rheumatoid arthritis, the majority of the excess crosslink in free form in biological fluids will be, in fact, due to the resorption of bone.
Since other connective tissues, such as cartilage, for the most part contain only Pyd, not Dpd, an elevation in the ratio of Pyd/Dpd may indicate diseases associated with such damage.
While immunoassays using the antibodies of the invention are convenient, the native free Pyd and Dpd crosslinks can also be determined in a variety of ways.
Since the pyridinoline linkage is fluorescent, direct chromatography of the sample of biological fluid as described in the art can result in separation of Dpd from Pyd and of the glycosylated forms of Pyd and the II I- IY ~I8~ CIP~ -23intensity of the fluorescence of the peaks obtained provides an index to quantitation.
In the methods of the invention, therefore, the native free crosslinks can be determined either as a group or individually by determining tha intensity of the fluorescence of the chromatographed material.
As set forth in PCT application W089/04491 referenced above, the quantity of crosslinks can also be determined using specific electrodes of appropriate redox potential for the ring system.
In addition to the use of the native free crosslink as an indicator of bone resorption, bone metabolic balance is advantageously determined by combining this S. determination with the determination of a marker for 15 formation of bone in the same or other appropriate biological fluid from the same individual. For example, such markers include procollagen type I, bone osteocalcin (also known as bone GLA protein or BGP); pro bone GLA protein, matrix GLA protein (MGP), bone specific proteins 20 such as bone specific sialoprotein, phosphoproteins, alkaline phosphatase, osteonectin or other noncollagenous bone proteins. Methods for determination of these merers are well known in the art. Suitable methods for determination of these markers can be found, for example, in Delmas, et al., J Born Min Res (1986) 1:333-337 (supi.a) for GLA.
The foregoing assays which provide an index to determination of.the metabolic status of tissues which generate collagen-derived crosslinks when degradation occurs, are useful in a variety of contexts. First, they are a method to assess an abnormal condition of a subject by indicating, for example, excessive bone resorption.
This may show, for example, the presence of an osteoporotic condition or the unfortunate metastatic i i I -c~ -24progress of a malignancy. Other known conditions characterized by excessive bone resorption include Paget's disease and hyperparathyroidism. Since the condition of the subject can be monitored continuously, application of these assays can also be used to monitor the progress of therapy administered to treat these or other conditions. The assays can also be used as a measure of toxicity as the administration of toxic substances often results in tissue degradation.
Thus, the assays may be applied in any situation wherein the metabolic condition of collagen crosslinkcontaining tissues can be used as an index of the condition, treatment, or effect of substances directly administered to the subject or to which the subject is 15 exposed in the environment.
The following examples are intended to illustrate but not to limit the invention.
Example 1 20 Assay for Native Free Crosslinks in Urine A. Isolation of U-Pyd and U-Dpd: Urine samples were collected from patients with Paget's disease or hyperparathyroidism (which contains elevated levels of free crosslinks) and from growing children (in which oi about 10-fold higher concentrations of crosslinks are present compared with normal adults). After concentration 10-fold by rotary evaporation, batches of the urine (20 liters) were subjected to partition chromatography batchwise on cellulose CF1 using butanol:acetic acid:water (4:1:1 v/v/v) as mobile phase.
The pyridinium crosslink-containing fraction, eluted from the stationary phase with water, was chromatographed on a column (3.2 x 150 cm) of Sephadex G-10 eluted with 0.2M acetic acid. Pooled fractions containing the crosslinks were then made 67 mM in Na+ and applied to a column (1.7 x 35 cm) of Dowex 50X-X8 ion-exchange resin equilibrated with 67 mM sodium citrate buffer, pH 2.75. After raising the column temperature to 60 0 C, elution with 67 mM sodium citrate was performed with a linear pH gradient from 2.75 to 5.50 over 500 ml. The column effluent was monitored by fluorescence (ex 325 nm/emm 400 nm) and the pooled fractions containing U-Pyd (364-377 ml) and U-Dpd (397- 416 ml) were desalted by gel filtration on Sephadex and evaporated to dryness. The yield from 20 liters of urine was 2.5 jmoles U-Pyd and 0.6 Amoles U-Dpd.
B. Results: The isolation procedure set forth in 15 paragraph A of this sample was applied to urine samples from individual patients and the amounts of U-Pyd and .U-Dpd were quantitated using fluorescence measurements relative to creatinine as is known in the art (supra).
The values obtained for normal individuals and in7 20 patients with bone disorders and arthritic diseases are shown in Table 2. Values are given as the mean SEM (n=6 in each group).
.0 UI_ I_ -26- Table 2 Patient Group U-Pyd U-Dpd (nmol/mmol creatinine) Normal controls Osteoporosis Paget's disease Hyperparathyroidism Rheumatoid arthritis Osteoarthritis 10.3 1.0 19.6 t 2.3 62.5 11.2 55.9 14.2 38.8 8.36 25.8 3.22 3.27 0.57 5.90 0.68 19.3 3.83 16.3 4.81 8.92 2.08 6.10 0.83 a.a These results show dramatically elevated levels of the free crosslinks in patients known to be suffering 15 from diseases characterized by excessive breakdown of connective tissue.
Table 3 shows the proportions of U-Pyd and U-Dpd as a percentage of the total crosslink measured after hydrolysis in the different patient groups.
9 t 9 a. a a a 99 I I -27- Table 3 Patient Group U-Pyd* U-Dpd* Normal controls 43.8 2.5 50.1 5.4 Osteoporosis 41.7 2.0 42.7 2.6 Paget's disease 46.5 2.4 47.4 4.1 Hyperparathyroidism 48.7 6.8 46.2 6.9 Rheumatoid arthritis 38.1 2.6 43.3 1.8 Osteoarthritis 43.4 3.9 47.0 2.2 Calculated as: (U-Pyd/total Pyd) x 100 and (U-Dpd/total Dpd) x 100. For all groups combined (n=36), the correlation coefficient between U-Pyd and total Pyd 15 was 0.929 (p<0.0001) and between U-Dpd and total Dpd was 0.952 (p<0.0001).
Since, as shown in Table 3, the percentage of U-Pyd and U-Dpd is relatively unchanged in patients with abnormal conditions as compared to controls, concentra- 20 tions of the free crosslinks in urine reflect the same increase in collagen degradation in diseases compared with the controls as do the total crosslinks measured after hydrolysis of the urine.
U-Pyd and U-Dpd therefore provide viable indices of collagen degradation to facilitate diagnosis and monitoring of diseases involving abnormalities of connective tissue metabolism.
C. Immunoassay: Native free crosslinks isolated by the method described in paragraph A of this example are used for the preparation of antigen. U-Pyd and U-Dpd are further purified by ion-exchange chromatography with 67 mM-sodium citrate buffer, pH 4.25 using a high-resolution Y C- i ii -28resin column of an amino acid analyzer (Locarte Co. Ltd., London, UK).
For immunization, the isolated crosslinks are covalently attached to bovine serum albumin using carbodiimide reagents and methods well known in the art.
Both monoclonal and polyclonal antibodies are raised against the urinary crosslink components. For the production of monoclonal antibodies, Balb/c mice are immunized with urinary crosslink-BSA conjugates, and hybridoma cell lines are prepared using standard techniques after fusions of cells from the spleen or lymph nodes with Ag8 myeloma cells. Polyclonal antibodies are raised in rabbits. Screening of both antisera and hybridoma cell media iS performed by ELISA using microtiter plates coated with the appropriate urinary crosslink-gelatin conjugate prepared as described by Robins, Biochem J (1982) 217:617-620.
Assays for each of the crosslink components present in free form in urine are performed by an inhibition 20 ELISA as follows: Urine samples (5 or 20 pl) or solutions containing 0.2-20 pmol of purified urinary crosslink reference standard are diluted to 110 Al with phosphate buffered saline containing 0.05% Tween-20 detergent (PBS-T), and are added to 110 Al of primary antibody, immunoreactive fragment, or antiserum diluted 1:5,000 1:20,000 in PBS- T. Each sample is prepared in triplicate in roundbottomed, 96-well microtiter plates which are then incubated overnight at room temperature.
Portions (200 gl) of the samples are transferred to flat-bottomed microtiter plates previously coated with gelatine conjugate containing the appropriate urinary crosslink component. After 30 minutes, the plate is washed with PBS-T (3 times) and the bound antibodies -29detected by standard techniques with a biotin-labeled antibody prepared against the species of the primary antibody combined with a streptavidin-peroxidase and peroxidase substrate detection system. Color development is measured at 492 nm using an automated microtiter plate reader. Samples containing the analyte decrease the binding of primary antibody to the plate and thus have reduced color concentration. The amount of free crosslinks in the sample is quantified with reference to curves from standards included on each plate computed using log-log plots.
The foregoing assay can be reformatted to be conducted directly by coating the sample suspected of containing antigen in the flat-bottom microtiter plate, 15 and adding labeled primary antibody directly to the wells. After washing, the amount of labeled antibody remaining in the testing solution is determined. A decrease in levels indicates the presence of antigen.
20 Example 2 Sources of Native Free Crosslink In order to determine a source for native free crosslinks usable as standards in the assays of the invention, the urine of a number of species of large animals was analyzed. In bovine urine, the Pyd/Dpd ratio is 12±2 with only about 15% as free crosslink; the values in sheep are similar except for only about 20-25% is free crosslink. In pig urine, the ratio of Pyd/Dpd is about 5±1 and the proportion of free crosslink relative to total is 42±5%. The concentrations of free crosslinks are about 380 nM for Pyd and 70 nM for Dpd.
Children's urine appears to give a better yield of Dpd than urine from adults. Some preferential loss of Dpd from pig urine occurs when CF-1 cellulose is used in I i the purification procedure, and overall recovery of Fyd is 40-50% for Pyd but only 20% for U-Dpd. Using children's urine as a starting material, recovery for both crosslinks is about Accordingly, both children's and pig urine are suitable sources for free crosslink standards.
As set forth above, the yield of crosslink in the diastereomeric form characteristic of native free crosslink could be improved by liberating total crosslinks in these sources by enzymatic hydrolysis procedures, such as the use of exopeptidases and glycosidases.
Example 3 15 Pvd/Dpd in Human Tissues Analyses of a range of different tissues has shown that the crosslink content of cortical bone is slightly higher than that of trabecular bone with a Pyd/Dpd ratio of about 4.2. Although Dpd was not detected in 20 cartilage, this crosslink was present in aorta and in ligaments. These results are summarized in Table 4.
Table 4 Tissue n Pvd Dd (residues/molecule) Articular cartilage 15 1.47 0.23 N.D.
Cortical bone 15 0.35 0.09 0.08 0.02 Trabecular bone 7 0.26 0.08 0.06 0.02 Aorta 14 0.30 0.07 0.07 0.01 Invertebral disc 25 1.14 0.11 N.D.
Ligaments 10 0.47 0.35 0.05 0.03
__I
-31- Both Pyd and Dpd are completely absent from the collagens of normal skin, nor are they present in immature or newly synthesized collagens.
Example 4 Determination of Free Crosslinks in Osteoporosis Patient Urine Sixty-four postmenopausal women with vertebral fractures (type I osteoporosis) aged 53 to 74 years (mean SD, 64 5 years) were studied. All women had lumbar spin bone mineral density below the fracture threshold of .00 0.98 g/cm 2 as measured by dual-photon absorptiometry and spine radiographs showing three or more grade 1 fractures or one or more grade 2 fractures. No other secondary 15 cause for the osteoporosis was identified.
As a control group, 67 postmenopausal women with mean SD) age of 65 6 years (range 50 to 79 years) were studied. All women had normal spin radiographs and had lumbar spine bone mineral densities within the normal range for age as measured by dual-photon absorptiometry.
None had any illness or were taking drugs known to affect bone metabolism.
For measurements of hydroxyproline, the subjects were maintained on a gelatin-free diet for three days prior to the study. Urine samples were collected and alic-ucts were stored at -70 0 C until analyzed. The total crosslinks were measured essentially as described previously (Black, et al., Anal Biochem (1988) 169:197-203; Seibel, et al., J Rheumatol (1989) 16:964-970). For the determination of U-Pyd and U-Dpd in unhydrolyzed urine, 0.5 ml portions were processed directly by partition chromatography on CF1 cellulose (which separates the free from peptide-derivatized forms prior to the HPLC step; HPLC was conducted as for the I i, I R -32hydrolyzed samples). Hydroxyproline in acid hydrolysates of urine was measured by HPLC (Dawson, et al., Clin Chem (1988) 34:1572-1574).
Measurements of native free pyridinium crosslinks and of total hydroxyproline in urine for the control and osteoporotic groups are shown in Table 5. The results showed that the excretion of the bone-specific crosslink, U-Dpd, was significantly higher in the osteoporotic group compared with the controls.
Table Osteoporotic Controls nmol/mmol nmol/24h nmol/mmol nmol/24h creatinine creatinine 15 U-Pyd 21.4+6.6** 170+47 18.4+5.8 151±49 U-Dpd 45+14*** 4.6+1.7 37+13 U-Pyd.Gal.Glc 5.2+2.1 41±15 4.6+2.0 38+16 Hydroxyproline 21.4+7.4** 175+66 18.2±6.7 156±77 (x 10 3 20 SStatistical significance (Student's t-test) of the difference compared with the corresponding control group is shown: p 0.05; p 0.01; p 0.001 "i Differences were less marked for U-Pyd; the values for the glycosylated derivative, U-Pyd.Gal.Glc, were not statistically different. Linear regression analysis showed that there were highly significant correlations between values expressed as creatinine ratios and as the total 24h excretion for both U-Pyd (r=0.80) and U-Dpd This observation is consistent with the finding that there were no significant variations diurnally in crosslink excretion for healthy male or i I;- -33female volunteers McLaren and S.P. Robins, unpublished results).
There were significant correlations of U- Dpd with hydroxyproline which were more marked in the osteoporotic group (r=0.53; p<0.001) than in the controls (r=0.21; The relationship between U-Pyd and hydroxyproline was similar with correlation coefficients for the osteoporotic and control groups of r=0.45 (p<0.001) and r=0.34 respectively.
For samples where both free and total crosslinks were measured, there were highly significant correlations between these values. For deoxypyridinoline, the correlation coefficients for the osteoporotic group (n=25) and control group (n=24) were 15 0.90 and 0.84, respectively; the corresponding correlations for pyridinoline were r=0.96 and r=0.85.
S3 i; PI
Claims (8)
1. A method of screening for or monitoring a bone metabolism abnormality characterized by increased collagen degradation in a human subject, the method comprising determining the level of peptide-free, non-glycosylated pyridinoline (N-Pyd) or peptide-free deoxypyridinoline (N-Dpd) in a non-hydrolysed sample of biological fluid obtained from a human subject and comparing the level so 10 determined with a level characteristic of normal subjects, wherein an elevated determined level is indicative of a bone metabolism abnormality. 8
2. The method according to claim 1, wherein said bone metabolism abnormality is osteoporosis, hyperparathyroidism, rheumatoid arthritis, osteoarthritis, Paget's disease, or a malignant tumor or metastatic cancer in bone.
3. The method according to claim 1 or claim 2, wherein the level determined is the level of N-Pyd.
4. The method according to claim 1 or claim 2, wherein the level determined is the level of N-Dpd.
The method according to any preceding claim, wherein the biological fluid is urine.
6. The method according to any of claims 1 to 4, wherein the biological fluid is serum.
7. A kit for immunoassay determination of the amount or concentration of one or more native free cross- links in a biological fluid, said crosslink selected from peptide-free, non-glycosylated pyridinoline (N-Pyd) or peptide-free, deoxypyridinoline (N-Dpd), which comprises a 0lv, I II set of containers at least one of which contains a composition containing an antibody or immunologically reactive fragment thereof, said composition specifically immunoreactive with one or both of said N-Pyd and N-Dpd and at least one of which containers contains an additional reagent for conduct of said immunoassay along with instructions for the conduct of said assay.
8. The kit of claim 7 which further includes a set .0 of containers at least one of which contains a composition containing an antibody or immunologically reactive fragment thereof, said composition specifically immuno- reactive with one or more bone formation indicators. e o a r r Dated this tenth day of December 1996 THE ROWETT RESEARCH INSTITUTE Patent Attorneys for the Applicant: F.B. RICE CO. it i i ~s I ABSTRACT A method of screening for the presence of a bone metabolism abnormality characteristic of osteoporosis, hyperparathyroidism, rheumatoid arthritis, osteoarthritis or Pagets disease. The method includes determining the level of peptide-free, non-glycosylated pyridinoline (U- Pyd) or peptide-free deoxypyridinoline (U-Dpd) in a non- hydrolysed sample of a biological fluid obtained from a human subject and comparing the level so determined with the level in normal subjects, wherein an elevated determined level is indicative of a bone metabolism abnormality. *aao ooe *0 oo *O 'I-
AU68648/94A
1989-12-30
1994-07-21
Method to detect bone and other connective tissue disorders in humans and animals
Expired
AU682188B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
GB8929366
1989-12-30
GB898929366A
GB8929366D0
(en)
1989-12-30
1989-12-30
Method to detect connective tissue disorder in humans and animals
Related Parent Applications (1)
Application Number
Title
Priority Date
Filing Date
AU70659/91A
Division
AU648774B2
(en)
1989-12-30
1990-12-28
Method to detect bone and other connective tissue disorders in humans and animals
Publications (2)
Publication Number
Publication Date
AU6864894A
AU6864894A
(en)
1994-11-24
AU682188B2
true
AU682188B2
(en)
1997-09-25
Family
ID=10668604
Family Applications (2)
Application Number
Title
Priority Date
Filing Date
AU70659/91A
Expired
AU648774B2
(en)
1989-12-30
1990-12-28
Method to detect bone and other connective tissue disorders in humans and animals
AU68648/94A
Expired
AU682188B2
(en)
1989-12-30
1994-07-21
Method to detect bone and other connective tissue disorders in humans and animals
Family Applications Before (1)
Application Number
Title
Priority Date
Filing Date
AU70659/91A
Expired
AU648774B2
(en)
1989-12-30
1990-12-28
Method to detect bone and other connective tissue disorders in humans and animals
Country Status (17)
Country
Link
US
(2)
US5700694A
(en)
EP
(2)
EP0507831B1
(en)
JP
(3)
JPH087212B2
(en)
KR
(1)
KR0138503B1
(en)
AT
(2)
ATE122467T1
(en)
AU
(2)
AU648774B2
(en)
BR
(1)
BR9007969A
(en)
CA
(2)
CA2069611C
(en)
DE
(2)
DE69033511T2
(en)
DK
(1)
DK0507831T3
(en)
ES
(2)
ES2147761T3
(en)
FI
(1)
FI923028A
(en)
GB
(1)
GB8929366D0
(en)
GR
(1)
GR3016998T3
(en)
HU
(1)
HUT64421A
(en)
NO
(1)
NO304760B1
(en)
WO
(1)
WO1991010141A1
(en)
Families Citing this family (15)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US6121002A
(en)
*
1990-12-26
2000-09-19
The Rowett Research Institute
Method to detect bone and other connective tissue disorders in humans and animals
GB9202139D0
(en)
*
1992-01-31
1992-03-18
Sandoz Ltd
Improvements in or relating to organic compounds
EP0561297B1
(en)
*
1992-03-19
1998-10-14
Hoechst Marion Roussel, Ltd.
Tissue antigen and diagnostic method for human osteoporosis using the same
US5527715A
(en)
*
1992-07-31
1996-06-18
Metra Biosystems, Inc.
Method and kit for pyridinoline assay
US5620861A
(en)
*
1992-07-31
1997-04-15
Metra Biosystems, Inc.
Method and kit for pyridinium crosslink assay
AU2481992A
(en)
*
1992-08-28
1994-03-29
Rowett Research Institute, The
Method to monitor drug therapy and assess metastasis
US5736344A
(en)
*
1992-12-17
1998-04-07
Metra Biosystems, Inc.
Serum pyridinium crosslinks assay
US5756361A
(en)
*
1992-12-17
1998-05-26
Metra Biosystems, Inc.
Screening method for periodontal disease
JPH0792165A
(en)
*
1993-09-21
1995-04-07
Hoechst Japan Ltd
Diagnostic agent for osteoporosis
US5661039A
(en)
*
1995-03-01
1997-08-26
Metra Biosystems, Inc.
Perspiration assay for bone resorption
US5972623A
(en)
*
1997-07-31
1999-10-26
Metra Biosystems, Inc.
Collagen-peptide assay method
US6033918A
(en)
*
1997-11-10
2000-03-07
Bayer Corporation
Method and device for the detection of analyte in a fluid sample
EP1064554A1
(en)
*
1998-03-27
2001-01-03
Markus Seibel
Determination of the probability of bone metastases in patients with primary carcinomas
US6197592B1
(en)
*
1999-07-15
2001-03-06
Bio-Rad Laboratories, Inc.
Clinical control materials for detection of bone resorptive markers
JP2004510981A
(en)
*
2000-10-03
2004-04-08
ロウェット、リサーチ、インスティテュート
Method for measuring pyrrole-containing biological compound and pyrrole-containing biological compound
Citations (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
WO1989004491A1
(en)
*
1987-11-06
1989-05-18
Washington Research Foundation
Urinary assay for measuring bone resorption
WO1989012824A1
(en)
*
1988-06-25
1989-12-28
The Rowett Research Institute
Method of monitoring collagen degradation
WO1991008474A1
(en)
*
1989-12-04
1991-06-13
Ecossensors Limited
Improvements in and relating to microelectrodes and amperometric assays
Family Cites Families (4)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5300434A
(en)
*
1987-11-06
1994-04-05
Washington Research Foundation
Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US5283197A
(en)
*
1988-06-25
1994-02-01
The Rowett Research Institute
Method of monitoring collagen degradation
US5620861A
(en)
*
1992-07-31
1997-04-15
Metra Biosystems, Inc.
Method and kit for pyridinium crosslink assay
FI106326B
(en)
*
1996-09-23
2001-01-15
Tellabs Oy
Wiring to adapt the echo cancellation multi speed modem to the line, and wiring method
1989
1989-12-30
GB
GB898929366A
patent/GB8929366D0/en
active
Pending
1990
1990-12-28
DE
DE69033511T
patent/DE69033511T2/en
not_active
Expired - Lifetime
1990-12-28
CA
CA002069611A
patent/CA2069611C/en
not_active
Expired - Lifetime
1990-12-28
ES
ES94108293T
patent/ES2147761T3/en
not_active
Expired - Lifetime
1990-12-28
AU
AU70659/91A
patent/AU648774B2/en
not_active
Expired
1990-12-28
JP
JP3502284A
patent/JPH087212B2/en
not_active
Expired - Lifetime
1990-12-28
EP
EP91901884A
patent/EP0507831B1/en
not_active
Expired - Lifetime
1990-12-28
EP
EP94108293A
patent/EP0618448B1/en
not_active
Expired - Lifetime
1990-12-28
AT
AT91901884T
patent/ATE122467T1/en
not_active
IP Right Cessation
1990-12-28
BR
BR909007969A
patent/BR9007969A/en
not_active
IP Right Cessation
1990-12-28
HU
HU9202178A
patent/HUT64421A/en
unknown
1990-12-28
DK
DK91901884.6T
patent/DK0507831T3/en
active
1990-12-28
ES
ES91901884T
patent/ES2071979T3/en
not_active
Expired - Lifetime
1990-12-28
WO
PCT/GB1990/002030
patent/WO1991010141A1/en
active
IP Right Grant
1990-12-28
CA
CA002271544A
patent/CA2271544C/en
not_active
Expired - Lifetime
1990-12-28
DE
DE69019375T
patent/DE69019375T2/en
not_active
Expired - Fee Related
1990-12-28
AT
AT94108293T
patent/ATE191976T1/en
active
1992
1992-06-29
NO
NO922084A
patent/NO304760B1/en
not_active
IP Right Cessation
1992-06-30
KR
KR92701562A
patent/KR0138503B1/en
not_active
IP Right Cessation
1992-06-30
FI
FI923028A
patent/FI923028A/en
unknown
1994
1994-07-21
AU
AU68648/94A
patent/AU682188B2/en
not_active
Expired
1995
1995-06-06
US
US08/485,823
patent/US5700694A/en
not_active
Expired - Lifetime
1995-06-06
US
US08/471,364
patent/US5700693A/en
not_active
Expired - Lifetime
1995-08-02
GR
GR950402115T
patent/GR3016998T3/en
unknown
1997
1997-04-30
JP
JP11243097A
patent/JP3224356B2/en
not_active
Expired - Fee Related
2000
2000-07-05
JP
JP2000204308A
patent/JP2001050958A/en
active
Pending
Patent Citations (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
WO1989004491A1
(en)
*
1987-11-06
1989-05-18
Washington Research Foundation
Urinary assay for measuring bone resorption
WO1989012824A1
(en)
*
1988-06-25
1989-12-28
The Rowett Research Institute
Method of monitoring collagen degradation
WO1991008474A1
(en)
*
1989-12-04
1991-06-13
Ecossensors Limited
Improvements in and relating to microelectrodes and amperometric assays
Also Published As
Publication number
Publication date
CA2271544C
(en)
2006-01-17
NO922573L
(en)
1992-06-29
ATE191976T1
(en)
2000-05-15
NO922573D0
(en)
1992-06-29
EP0618448A1
(en)
1994-10-05
HU9202178D0
(en)
1992-10-28
DE69019375T2
(en)
1995-09-14
KR0138503B1
(en)
1998-05-15
DE69033511T2
(en)
2000-11-16
GB8929366D0
(en)
1990-02-28
AU7065991A
(en)
1991-07-24
DE69033511D1
(en)
2000-05-25
JPH05502942A
(en)
1993-05-20
US5700694A
(en)
1997-12-23
WO1991010141A1
(en)
1991-07-11
CA2069611C
(en)
1999-08-10
NO304760B1
(en)
1999-02-08
AU648774B2
(en)
1994-05-05
CA2271544A1
(en)
1991-07-01
CA2069611A1
(en)
1991-07-01
EP0618448B1
(en)
2000-04-19
ES2071979T3
(en)
1995-07-01
EP0507831B1
(en)
1995-05-10
ATE122467T1
(en)
1995-05-15
BR9007969A
(en)
1993-02-02
JP2001050958A
(en)
2001-02-23
JP3224356B2
(en)
2001-10-29
HUT64421A
(en)
1993-12-28
EP0507831A1
(en)
1992-10-14
AU6864894A
(en)
1994-11-24
JPH1045800A
(en)
1998-02-17
DE69019375D1
(en)
1995-06-14
US5700693A
(en)
1997-12-23
ES2147761T3
(en)
2000-10-01
FI923028A0
(en)
1992-06-30
FI923028A
(en)
1992-06-30
GR3016998T3
(en)
1995-11-30
JPH087212B2
(en)
1996-01-29
DK0507831T3
(en)
1995-10-09
Similar Documents
Publication
Publication Date
Title
AU682188B2
(en)
1997-09-25
Method to detect bone and other connective tissue disorders in humans and animals
JP3790727B2
(en)
2006-06-28
Methods for measuring collagen fragments in body fluids, test kits and means for carrying out the methods, and methods and uses of the methods for diagnosing the presence of diseases associated with collagen metabolism
KR0148619B1
(en)
1998-12-01
Method of determination of pivka-x and reagent therefor
AU752227B2
(en)
2002-09-12
Collagen-peptide assay method
US6210902B1
(en)
2001-04-03
Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
US6117646A
(en)
2000-09-12
Assaying protein fragments in body fluids
EP0787301B1
(en)
2001-02-14
Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
US6121002A
(en)
2000-09-19
Method to detect bone and other connective tissue disorders in humans and animals
US5661039A
(en)
1997-08-26
Perspiration assay for bone resorption
EP0015755B1
(en)
1984-08-08
Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors
US20100233737A1
(en)
2010-09-16
Marker specific to an oxidative degradation of tissues containing type iii collagen, means and methods and kits for the diagnosis, monitoring or prognosis of pathologies targeted by this marker
WO1994006015A1
(en)
1994-03-17
Method to monitor drug therapy and assess metastasis
KR100460292B1
(en)
2005-04-06
Protein fragment testing in body fluids
Download PDF in English
